TABLE 2.
TFV-DP cervical and rectal PKs for a subcutaneous implant at different zero-order release rates for 28 consecutive days
| Release rate (mg/day) | Simulated TFV-DP concn (fmol/106 cells; mean ± SD) ina: |
||
|---|---|---|---|
| PBMCs | Cervical tissue | Rectal tissue | |
| 1.6 | 56.6 ± 15.8 | 1.72 ± 0.38 | 1.11 ± 0.25 |
| 1.5 | 51.7 ± 13.5 | 1.63 ± 0.42 | 1.05 ± 0.27 |
| 1.4 | 49.3 ± 10.3 | 1.52 ± 0.32 | 0.98 ± 0.21 |
| 1.3 | 46.3 ± 11.1 | 1.45 ± 0.36 | 0.94 ± 0.23 |
a
Average ratios of 0.031 and 0.02 for TFV-DP cervical/TFV-DP PBMC and TFV-DP rectal/TFV-DP PBMC were used for computation of TFV-DP concentrations in cervical and rectal tissues, respectively.